Nathalie Guylaine Bérubé

Nathalie Guylaine Bérubé

Auto-generated profile, based on publicly available information

Nathalie Guylaine Bérubé

Affiliations Department of Anatomy & Cell Biology, Western University, London, Ontario, Canada, Department of Paediatrics, Western University, London, Ontario, Canada, Department of Oncology, Western University, London, Ontario, Canada, Division of Genetics & Development, Children’s Health Research Institute, London, Ontario, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2008 in Journal of Cell Biology
Verified
Journal Article
Open access
KRKieran Ritchie
Kieran Ritchie
CSClaudia Seah
Claudia Seah
JMJana Moulin
Jana Moulin
CIChristian Isaac
Christian Isaac
FDFrederick Dick
Frederick Dick
NBNathalie G. Bérubé
Nathalie G. Bérubé
αThalassemia/mental retardation X linked (ATRX) is a switch/sucrose nonfermenting-type ATPase localized at pericentromeric heterochromatin in mouse and human cells. Human ATRX mutations give rise to mental retardation syndromes characterized by developmental delay, facial dysmorphisms, cognitive deficits, and microcephaly and the loss of ATRX in the mouse brain leads to reduced cortical size. We find that ATRX is required for normal mitotic progression in human cultured cells and in neuroprogenitors. Using live cell imaging, we show that the transition from prometaphase to metaphase is prolonged in ATRX-depleted cells and is accompanied by defective sister chromatid cohesion and congression at the metaphase plate. We also demonstrate that loss of ATRX in the embryonic mouse brain induces mitotic defects in neuroprogenitors in vivo with evidence of abnormal chromosome congression and segregation. These findings reveal that ATRX contributes to chromosome dynamics during mitosis and provide a possible cellular explanation for reduced cortical size and abnormal brain development associated with ATRX deficiency.

8 November 2017 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SIShigeki Iwase
Shigeki Iwase
NBNathalie G. Bérubé
Nathalie G. Bérubé
ZZZhaolan Zhou
Zhaolan Zhou
NKNael Nadif Kasri
Nael Nadif Kasri
EBElena Battaglioli
Elena Battaglioli
ABAngel Barco
Angel Barco
Intellectual disability (ID) is a prevailing neurodevelopmental condition associated with impaired cognitive and adaptive behaviors. Many chromatin-modifying enzymes and other epigenetic regulators have been genetically associated with ID disorders (IDDs). Here we review how alterations in the function of histone modifiers, chromatin remodelers, and methyl-DNA binding proteins contribute to neurodevelopmental defects and altered brain plasticity. We also discuss how progress in human genetics has led to the generation of mouse models that unveil the molecular etiology of ID, and outline the direction in which this field is moving to identify therapeutic strategies for IDDs. Importantly, because the chromatin regulators linked to IDDs often target common downstream genes and cellular processes, the impact of research in individual syndromes goes well beyond each syndrome and can also contribute to the understanding and therapy of other IDDs. Furthermore, the investigation of these disorders helps us to understand the role of chromatin regulators in brain development, plasticity, and gene expression, thereby answering fundamental questions in neurobiology.

8 April 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LWL. Ashley Watson
L. Ashley Watson
LSLauren A. Solomon
Lauren A. Solomon
JLJennifer Ruizhe Li
Jennifer Ruizhe Li
YJYan Jiang
Yan Jiang
MEMatthew Edwards
Matthew Edwards
NBNathalie G. Bérubé
Nathalie G. Bérubé
Human ATRX mutations are associated with cognitive deficits, developmental abnormalities, and cancer. We show that the Atrx-null embryonic mouse brain accumulates replicative damage at telomeres and pericentromeric heterochromatin, which is exacerbated by loss of p53 and linked to ATM activation. ATRX-deficient neuroprogenitors exhibited higher incidence of telomere fusions and increased sensitivity to replication stress–inducing drugs. Treatment of Atrx-null neuroprogenitors with the G-quadruplex (G4) ligand telomestatin increased DNA damage, indicating that ATRX likely aids in the replication of telomeric G4-DNA structures. Unexpectedly, mutant mice displayed reduced growth, shortened life span, lordokyphosis, cataracts, heart enlargement, and hypoglycemia, as well as reduction of mineral bone density, trabecular bone content, and subcutaneous fat. We show that a subset of these defects can be attributed to loss of ATRX in the embryonic anterior pituitary that resulted in low circulating levels of thyroxine and IGF-1. Our findings suggest that loss of ATRX increases DNA damage locally in the forebrain and anterior pituitary and causes tissue attrition and other systemic defects similar to those seen in aging.

1 December 2014 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
MLMichael A. Levy
Michael A. Levy
KKKristin D. Kernohan
Kristin D. Kernohan
YJYan Jiang
Yan Jiang
NBNathalie G. Bérubé
Nathalie G. Bérubé
ATRX is a chromatin remodeling protein involved in deposition of the histone variant H3.3 at telomeres and pericentromeric heterochromatin. It also influences the expression level of specific genes; however, deposition of H3.3 at transcribed genes is currently thought to occur independently of ATRX. We focused on a set of genes, including the autism susceptibility gene Neuroligin 4 (Nlgn4), that exhibit decreased expression in ATRX-null cells to investigate the mechanisms used by ATRX to promote gene transcription. Overall TERRA levels, as well as DNA methylation and histone modifications at ATRX target genes are not altered and thus cannot explain transcriptional dysregulation. We found that ATRX does not associate with the promoter of these genes, but rather binds within regions of the gene body corresponding to high H3.3 occupancy. These intragenic regions consist of guanine-rich DNA sequences predicted to form non-B DNA structures called G-quadruplexes during transcriptional elongation. We demonstrate that ATRX deficiency corresponds to reduced H3.3 incorporation and stalling of RNA polymerase II at these G-rich intragenic sites. These findings suggest that ATRX promotes the incorporation of histone H3.3 at particular transcribed genes and facilitates transcriptional elongation through G-rich sequences. The inability to transcribe genes such as Nlgn4 could cause deficits in neuronal connectivity and cognition associated with ATRX mutations in humans.

19 February 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
LWL. Ashley Watson
L. Ashley Watson
XWXu Wang
Xu Wang
AEAdrienne Elbert
Adrienne Elbert
KKKristin D. Kernohan
Kristin D. Kernohan
NGNiels Galjart
Niels Galjart
NBNathalie G. Bérubé
Nathalie G. Bérubé
An increasing number of proteins involved in genome organization have been implicated in neurodevelopmental disorders, highlighting the importance of chromatin architecture in the developing CNS. The CCCTC-binding factor (CTCF) is a zinc finger DNA binding protein involved in higher-order chromatin organization, and mutations in the humanCTCFgene cause an intellectual disability syndrome associated with microcephaly. However, information on CTCF functionin vivoin the developing brain is lacking. To address this gap, we conditionally inactivated theCtcfgene at early stages of mouse brain development. Cre-mediatedCtcfdeletion in the telencephalon and anterior retina at embryonic day 8.5 triggered upregulation of the p53 effector PUMA (p53 upregulated modulator of apoptosis), resulting in massive apoptosis and profound ablation of telencephalic structures. Inactivation ofCtcfseveral days later at E11 also resulted in PUMA upregulation and increased apoptotic cell death, and theCtcf-null forebrain was hypocellular and disorganized at birth. Although deletion of bothCtcfandPumain the embryonic brain efficiently rescuedCtcf-null progenitor cell apoptosis, it failed to improve neonatal hypocellularity due to decreased proliferative capacity of rescued apical and outer radial glia progenitor cells. This was exacerbated by an independent effect of CTCF loss that resulted in depletion of the progenitor pool due to premature neurogenesis earlier in development. Our findings demonstrate that CTCF activities are required for two distinct events in early cortex formation: first, to correctly regulate the balance between neuroprogenitor cell proliferation and differentiation, and second, for the survival of neuroprogenitor cells, providing new clues regarding the contributions of CTCF in microcephaly/intellectual disability syndrome pathologies.

10 March 2017 in Epigenetics & Chromatin
Verified
Journal Article
Open access
PDF file
LSLaila C. Schenkel
Laila C. Schenkel
KKKristin D. Kernohan
Kristin D. Kernohan
AMArran McBride
Arran McBride
DRDitta Reina
Ditta Reina
AHAmanda Hodge
Amanda Hodge
BSBekim Sadikovic
Bekim Sadikovic
Alpha thalassemia/mental retardation X-linked syndrome (ATR-X) is caused by a mutation at the chromatin regulator gene ATRX. The mechanisms involved in the ATR-X pathology are not completely understood, but may involve epigenetic modifications. ATRX has been linked to the regulation of histone H3 and DNA methylation, while mutations in the ATRX gene may lead to the downstream epigenetic and transcriptional effects. Elucidating the underlying epigenetic mechanisms altered in ATR-X will provide a better understanding about the pathobiology of this disease, as well as provide novel diagnostic biomarkers. We performed genome-wide DNA methylation assessment of the peripheral blood samples from 18 patients with ATR-X and compared it to 210 controls. We demonstrated the evidence of a unique and highly specific DNA methylation “epi-signature” in the peripheral blood of ATRX patients, which was corroborated by targeted bisulfite sequencing experiments. Although genomically represented, differentially methylated regions showed evidence of preferential clustering in pericentromeric and telometric chromosomal regions, areas where ATRX has multiple functions related to maintenance of heterochromatin and genomic integrity. Most significant methylation changes in the 14 genomic loci provide a unique epigenetic signature for this syndrome that may be used as a highly sensitive and specific diagnostic biomarker to support the diagnosis of ATR-X, particularly in patients with phenotypic complexity and in patients with ATRX gene sequence variants of unknown significance.